Regdanvimab

Regdanvimab is a monoclonal antibody under investigation for the treatment of coronavirus disease 2019 (COVID‑19).
On 4 March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started a rolling review of data on regdanvimab.
Society and culture.
Names.
Regdanvimab is the proposed international nonproprietary name (pINN).